These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31862503)

  • 1. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
    Choi DT; Puenpatom A; Yu X; Erickson KF; Kanwal F; El-Serag HB; Kramer JR
    Antiviral Res; 2020 Feb; 174():104698. PubMed ID: 31862503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
    Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
    Kramer JR; Puenpatom A; Erickson KF; Cao Y; Smith D; El-Serag HB; Kanwal F
    J Viral Hepat; 2018 Nov; 25(11):1270-1279. PubMed ID: 29851265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
    PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Elbasha E; Greaves W; Roth D; Nwankwo C
    J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam.
    Nwankwo C; Corman SL; Elbasha EH
    J Infect Public Health; 2019; 12(4):502-508. PubMed ID: 30711348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    Kumada H; Suzuki Y; Karino Y; Chayama K; Kawada N; Okanoue T; Itoh Y; Mochida S; Toyoda H; Yoshiji H; Takaki S; Yatsuzuka N; Yodoya E; Iwasa T; Fujimoto G; Robertson MN; Black S; Caro L; Wahl J
    J Gastroenterol; 2017 Apr; 52(4):520-533. PubMed ID: 27873094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.
    Kramer JR; Puenpatom A; Cao Y; Yu X; El-Serag HB; Kanwal F
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):445-453. PubMed ID: 35077656
    [No Abstract]   [Full Text] [Related]  

  • 9. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.
    Liu CH; Peng CY; Fang YJ; Kao WY; Yang SS; Lin CK; Lai HC; Su WP; Fang SU; Chang CC; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
    Sci Rep; 2020 Jun; 10(1):9180. PubMed ID: 32513953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
    Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
    J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
    Brown A; Hézode C; Zuckerman E; Foster GR; Zekry A; Roberts SK; Lahser F; Durkan C; Badshah C; Zhang B; Robertson M; Wahl J; Barr E; Haber B;
    J Viral Hepat; 2018 May; 25(5):457-464. PubMed ID: 29152828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
    Caro L; Wenning L; Feng HP; Guo Z; Du L; Bhagunde P; Fandozzi C; Panebianco D; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    Eur J Clin Pharmacol; 2019 May; 75(5):665-675. PubMed ID: 30680407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
    Elbasha EH; Robertson MN; Nwankwo C
    Aliment Pharmacol Ther; 2017 Feb; 45(3):455-467. PubMed ID: 27910116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.
    Cheng PN; Chen CY; Yu ML; Lin CC; Lin CY; Peng CY; Tseng KC; Lo CC; Tseng IH; Liu CJ
    J Microbiol Immunol Infect; 2021 Aug; 54(4):588-595. PubMed ID: 32499107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.
    Atsukawa M; Tsubota A; Toyoda H; Takaguchi K; Kondo C; Okubo T; Hiraoka A; Michitaka K; Fujioka S; Uojima H; Watanabe T; Ikeda H; Asano T; Ishikawa T; Matsumoto Y; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Mikami S; Tanaka Y; Kumada T; Iwakiri K
    J Gastroenterol Hepatol; 2019 Feb; 34(2):364-369. PubMed ID: 30144366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
    Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S1-S8. PubMed ID: 32539296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
    Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H; Martin P; Pol S; Londoño MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W
    Lancet; 2015 Oct; 386(10003):1537-45. PubMed ID: 26456905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
    Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.